Literature DB >> 19865112

Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias.

N Carbuccia, V Trouplin, V Gelsi-Boyer, A Murati, J Rocquain, J Adélaïde, S Olschwang, L Xerri, N Vey, M Chaffanet, D Birnbaum, M J Mozziconacci.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19865112     DOI： 10.1038/leu.2009.218

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  39 in total

Review 1.  Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer.

Authors:  Martin Sauvageau; Guy Sauvageau
Journal:  Cell Stem Cell       Date:  2010-09-03       Impact factor: 24.633

Review 2.  Molecular therapy for acute myeloid leukaemia.

Authors:  Catherine C Coombs; Martin S Tallman; Ross L Levine
Journal:  Nat Rev Clin Oncol       Date:  2015-12-01       Impact factor: 66.675

3.  Expression of myeloperoxidase in acute myeloid leukemia blasts mirrors the distinct DNA methylation pattern involving the downregulation of DNA methyltransferase DNMT3B.

Authors:  H Itonaga; D Imanishi; Y-F Wong; S Sato; K Ando; Y Sawayama; D Sasaki; K Tsuruda; H Hasegawa; Y Imaizumi; J Taguchi; H Tsushima; S Yoshida; T Fukushima; T Hata; Y Moriuchi; K Yanagihara; Y Miyazaki
Journal:  Leukemia       Date:  2014-01-10       Impact factor: 11.528

Review 4.  AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches.

Authors:  Megan A Hatlen; Lan Wang; Stephen D Nimer
Journal:  Front Med       Date:  2012-08-09       Impact factor: 4.592

5.  Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signals.

Authors:  Xudong Wu; Ida Holst Bekker-Jensen; Jesper Christensen; Kasper Dindler Rasmussen; Simone Sidoli; Yan Qi; Yu Kong; Xi Wang; Yajuan Cui; Zhijian Xiao; Guogang Xu; Kristine Williams; Juri Rappsilber; Casper Kaae Sønderby; Ole Winther; Ole N Jensen; Kristian Helin
Journal:  Cell Res       Date:  2015-10-16       Impact factor: 25.617

6.  The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration.

Authors:  O Abdel-Wahab; O Kilpivaara; J Patel; L Busque; R L Levine
Journal:  Leukemia       Date:  2010-07-01       Impact factor: 11.528

7.  ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

Authors:  Klaus H Metzeler; Heiko Becker; Kati Maharry; Michael D Radmacher; Jessica Kohlschmidt; Krzysztof Mrózek; Deedra Nicolet; Susan P Whitman; Yue-Zhong Wu; Sebastian Schwind; Bayard L Powell; Thomas H Carter; Meir Wetzler; Joseph O Moore; Jonathan E Kolitz; Maria R Baer; Andrew J Carroll; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield
Journal:  Blood       Date:  2011-10-26       Impact factor: 22.113

8.  Recent advances in the treatment of acute myeloid leukemia.

Authors:  Omar Abdel-Wahab; Ross L Levine
Journal:  F1000 Med Rep       Date:  2010-07-22

Review 9.  Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications.

Authors:  Wei Wang; Jiang-Jiang Qin; Sukesh Voruganti; Subhasree Nag; Jianwei Zhou; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2015-07-30       Impact factor: 12.944

Review 10.  Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms.

Authors:  Omar Abdel-Wahab; Ayalew Tefferi; Ross L Levine
Journal:  Hematol Oncol Clin North Am       Date:  2012-08-21       Impact factor: 3.722
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.